Illumina, Inc. (NASDAQ:ILMN) today announced five initial TruSight content sets for use in next-generation sequencing (NGS) in laboratory settings. Designed by recognized experts at leading institutions, the content sets offer cost-effective, streamlined, targeted sequencing for specific genetic diseases or conditions. Customers can immediately leverage this content to develop their own tests, and in the first half of 2013 will have the additional capability to augment the sets with custom content. These products, developed in conjunction with leading healthcare experts including Children’s Mercy Center for Pediatric Genomic Medicine, Kennedy Krieger Institute, The Institute of Cancer Research, London, and Partners HealthCare (see additional Illumina-Partners HealthCare news today), are designed to provide comprehensive evaluation of genes associated with the following:
- TruSight Autism used for the evaluation of autism, a condition affecting about 1 in 88 children;
- TruSight Cancer assists in identifying genetic causes of cancer and includes genes associated with common (e.g. breast, colorectal cancer) and rare cancers;
- TruSight Cardiomyopathy assists in identifying inherited causes of cardiomyopathy;
- TruSight Inherited Disease focuses on severe, recessive pediatric onset diseases; and
- TruSight Exome targets rare genetic diseases that affect as many as 10 million people per year worldwide, with content from the HGMD® (Human Gene Mutation Database).
“We are very excited about the value of the new content and how accessible it will be to laboratories,” said Dr. Stephen Kingsmore, Director, Children’s Mercy Center for Pediatric Genomic Medicine, in Kansas City, Mo. “Deploying this expert content on Illumina’s proven technology streamlines a lab’s operational efficiency and speed to results. Ultimately, we hope to improve patient care. That’s the true goal.”Added Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business, “Today, Illumina also announced a strategic alliance with Partners HealthCare to introduce next-generation sequencing clinical interpretation and reporting tools, via their GeneInsight® Suite platform. The combination of TruSight products and these new interpretation and reporting tools is a major step forward in realizing the benefits of next generation sequencing.” TruSight content sets are for research use only and not intended for diagnostic use. The products are now available for order with shipment to begin in Q4 2012. For more information, visit www.illumina.com/TruSight. About Illumina Illumina ( www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Forward-Looking Statements This release contains forward looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability of support for user custom content and the expected shipping date for TruSight Content Sets. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.